Introduction
Alzheimer's disease and Parkinson's disease have been suggested to have a common aetiology. ' 13 These neurodegenerative disorders share several pathological and neurochemical characteristics. Lewy bodies, one of the hallmarks of Parkinson's disease, are often observed in Alzheimer's disease.' 2 The Alzheimer type pathology is found more often in patients with advanced idiopathic Parkinson's disease than in the general population. In most studies of Parkinson's disease, patients have been observed to smoke less than control subjects.4 There is also some evidence that nicotine may improve information processing and attention in patients with Alzheimer's disease,67 which suggests that nicotine may have a protective role in Alzheimer's disease. To test this idea we studied smoking habits before the onset of dementia in patients with Alzheimer's disease and controls as part of a genetic and epidemiological study of Alzheimer's disease carried out in The Netherlands.
Subjects and methods
The study comprised all patients with Alzheimer's disease living in two areas ofThe Netherlands in whom the disease was diagnosed before the age of 70 and during January 1980 to July 1987. Ascertainment of patients and controls has been described in detail elsewhere.8 For this study the diagnosis of Alzheimer's disease was verified independently and all patients fulfilled the criteria for clinical diagnosis ofAlzheimer's disease of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).9 Dementias other than Alzheimer's disease, such as multi-infarct dementia and dementia secondary to alcoholism, depression, metabolic disorders, epilepsy, and other conditions, were excluded. Patients with symptoms of Parkinson's disease before the onset of Alzheimer's disease were also excluded.
The inclusion criteria for patients were: a score on the clinical dementia rating scale of more than 0 5"'; a score on the short portable mental status questionnaire of less than 20 (out of 30)"; a score of seven or less on the Hachinski scale'2; no evidence of abnormalities on computed tomography other than cerebral atrophy; and no evidence of focal dysfunction on electroencephalography. For each patient, a control matched for age (within five years) and sex was selected randomly from the population registry of the municipality where the patient lived.
Based on patients' family history of dementia BMJ VOLUME 302
Alzheimer's disease was classified as sporadic (in those with no first degree relatives with dementia) or familial (in those with one or more first degree relatives with dementia). We examined the pedigree of the families of patients for consistency with autosomal dominant inheritance of Alzheimer's disease. ended questions about medical treatment and admission to hospital. Full pedigree information on dementia and Parkinson's disease was obtained. All first degree relatives were listed, and we asked specifically about the occurrence of dementia and Parkinson's disease in them. To increase the validity of these data the information on family history was verified by a second first degree relative. If the patient had been admitted to hospital the diagnosis was checked in independent medical records.8
DATA ANALYSIS
We assessed the strength of the association between Alzheimer's disease, smoking, and other putative risk factors by the odds ratio as an estimate of the relative risk. 3 Relative risks are presented with 95% confidence intervals. Smoking was significantly correlated with alcohol intake (r=0 34; p=0 04) in controls, and we therefore used conditional logistic regression analysis to take alcohol consumption as well as sex and age into account. Modification of the relation between smoking and Alzheimer's disease by the established risk factors age, sex, and family history of dementia was tested. As there was a significant interaction between smoking history and family history of dementia (p=0 02 BMJ VOLUME 302 (19%) ofthe controls (relative risk 4-32; 95% confidence interval 2 71 to 6-82). Significantly more patients with Alzheimer's disease than controls had a first degree relative with Parkinson's disease (2 90; 1 11 to 8 49).
Fewer patients with Alzheimer's disease smoked than did control subjects (table II) . A significant inverse association with smoking was found in patients with familial Alzheimer's disease (those with one or more first degree relatives with dementia), whereas there was no evidence for an association with smoking in patients with sporadic Alzheimer's disease. The inverse association between familial Alzheimer's disease and smoking remained after restricting the analysis to patients and controls without a history of atherosclerotic cardiovascular disease (0-16; 0-06 to 0-45).
A negative trend for smoking was observed when comparing patients with Alzheimer's disease and controls: the risk of Alzheimer's disease decreased as the number of cigarettes smoked daily increased (table  III) . After exclusion of patients and controls with a history of atherosclerotic cardiovascular disease, the relative risks of Alzheimer's disease for smoking 1-10, 11-20, and more than 20 cigarettes daily were 0-81 (0 44 to 1-49), 0-67 (0-34 to 1-32), and 0-26 (0O11 to 0-61), respectively. A similar trend was observed when comparing patients and controls for the number of pack years they had smoked. The relative risk of Alzheimer's disease was 0-38 (0-13 to 1-10) for those who had smoked for 1-10 pack years, 0-29 (0-08 to 0-98) for 11-30 pack years, and 0-22 (0-06 to 0-77) for more than 30 pack years.
The families of 17 patients had a pedigree consistent with autosomal dominant inheritance of Alzheimer's disease. In these families 18 (33%) of the 56 affected siblings had smoked, compared with 73 (67%) of the 109 unaffected siblings (0-27; 0-11 to 0 67). To test whether smoking history modified the onset of disease, we used the data on six families in which there were patients with Alzheimer's disease who had smoked and patients with Alzheimer's disease who had never smoked (table IV) . There was a significantly later onset of 4-17 years in patients who smoked compared with non-smoking patients from the same family (standard error of the difference 1-35; p=0 03). The clinical diagnosis of Alzheimer's disease was confirmed at necropsy in two patients in family 1066 and one patient in family 1072.
Discussion
We observed a strong inverse relation between smoking and Alzheimer's disease. The association was restricted to patients with a family history of dementia and was independent of cardiovascular history and potential confounding variables such as age, sex, and alcohol consumption. The risk of Alzheimer's disease decreased as the number of cigarettes smoked daily increased. Within families in which Alzheimer's disease was apparently inherited as an autosomal dominant disorder we observed that the onset of Alzheimer's disease was later in smoking patients than in nonsmoking patients. We also found familial aggregation of Parkinson's disease with Alzheimer's disease, even though patients with Alzheimer's disease who had a history of Parkinson's disease were excluded. 8 Before interpreting these findings, we would like to raise some methodological issues. At present it is not possible to distinguish between patients with Alzheimer's disease primarily of genetic origin and those with disease primarily of environmental origin. We have therefore classified patients on the basis of their family history ofdementia, assuming that patients with a family history are more likely to have disease of genetic origin. This has probably introduced misclassification because relatives ofpatients with sporadic disease may carry the gene and express the disease later in life, whereas familial aggregation of Alzheimer's disease may be due to clustering of patients with non-genetic disease. The most likely effect of this misclassification is that it has made patients with familial and sporadic disease more similar. The difference in risk between familial and sporadic Alzheimer's disease may therefore be larger than we have reported.
Another methodological issue concerns data collection. Although we measured smoking habits in a symmetrical way in patients and controls,8 there is a possibility of bias: the non-response within the control group may have been associated with smoking, and relatives of patients with Alzheimer's disease may have underreported smoking habits. We consider it less likely, however, that these types of bias have occurred only in patients with a family history of dementia or their matched controls. As we observed no association of smoking with sporadic Alzheimer's disease the association with familial Alzheimer's disease is unlikely to be fully explained by these sources ofbias. Moreover, the comparison of age of onset between smoking and non-smoking patients largely overcomes the bias to which comparisons of patients with control subjects are prone.
Another possible source of bias is that the survival rate may have been higher in patients who did not smoke than in those who did. However, the association between smoking and familial Alzheimer's disease remained significant after excluding all patients and all controls with a history ofatherosclerotic cardiovascular disease, the commonest competing cause of death. Also, the finding of a later onset of disease in smoking Our finding of an inverse association between smoking and Alzheimer's disease should be interpreted with caution as it is not confirmed by prospective studies. Although the association is compatible with a protective effect of smoking for familial Alzheimer's disease, it has no relevance for prevention of Alzheimer's disease because of the adverse health effects of smoking. These findings may lead to interesting speculations, however, about why both familial Alzheimer's and Parkinson's disease may be inversely related to smoking. They may further suggest a joint aetiology of these disorders.
